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AbstrAct
Introduction Several retrospective or single-centre 
studies demonstrated the efficacy of transplacental 
treatment of fetal tachyarrhythmias. Our retrospective 
nationwide survey showed that the fetal therapy will 
be successful at an overall rate of 90%. For fetuses 
with hydrops, the treatment success rate will be 80%. 
However, standard protocol has not been established. 
The objective of this study is to evaluate the efficacy and 
safety of the protocol-defined transplacental treatment of 
fetal tachyarrhythmias. Participant recruitment began in 
October 2010.
Methods and analysis The current study is a multicentre, 
single-arm interventional study. A total of 50 fetuses 
will be enrolled from 15 Japanese institutions. The 
protocol-defined transplacental treatment is performed for 
singletons with sustained fetal tachyarrhythmia ≥180 bpm, 
with a diagnosis of supraventricular tachycardia or atrial 
flutter. Digoxin, sotalol, flecainide or a combination is used 
for transplacental treatment. The primary endpoint is 
disappearance of fetal tachyarrhythmias. The secondary 
endpoints are fetal death related to tachyarrhythmia, 
proportion of preterm birth, rate of caesarean section 
attributable to fetal arrhythmia, improvement in fetal 
hydrops, neonatal arrhythmia, neonatal central nervous 
system disorders and neonatal survival. Maternal, fetal and 
neonatal adverse events are evaluated at 1 month after 
birth. Growth and development are also evaluated at 18 
and 36 months of corrected age.
Ethics and dissemination The Institutional Review Board 
of the National Cerebral and Cardiovascular Center of 
Japan has approved this study. Our findings will be widely 
disseminated through conference presentations and peer-
reviewed publications.
trial registration number UMIN Clinical Trials Registry 
UMIN000004270.
IntroductIon
Fetal tachyarrhythmia develops in less than 
0.1% of pregnancies. The most common 
forms of tachyarrhythmia are supraventric-
ular tachycardia (SVT) and atrial flutter 
(AFL). Fetal arrhythmia with 1:1 atrioventric-
ular (AV) conduction at rates of 180–200 bpm 
might include some cases of sinus tachycardia 
such as infection, anaemia, fetal distress, 
medication use, trauma or hyperthyroidism 
in the mother.1 2 Fetal tachyarrhythmia results 
in a wide spectrum of outcomes, including 
spontaneous remission, heart failure, fetal 
hydrops and fetal death. In fetuses, severe 
or long-lasting tachyarrhythmia often leads 
to heart failure and fetal hydrops.3 4 Fetal 
hydrops has been reported in 30%–40% of 
fetuses with SVT and in 7%–43% of those 
with AFL.5 6 High incidences of fetal hydrops 
are associated with tachycardia lasting for 
12 or more hours. For fetuses with fetal 
hydrops, elective preterm delivery and other 
life-saving interventions are often attempted. 
Yet, studies have reported a 35% perinatal 
mortality rate with fetal hydrops. Since few 
studies have reported cases of fetal hydrops 
without preterm intervention, we cannot 
Antenatal antiarrhythmic treatment for 
fetal tachyarrhythmias: a study protocol 
for a prospective multicentre trial
Takekazu Miyoshi,1 Yasuki Maeno,2 Haruhiko Sago,3 Noboru Inamura,4 
Satoshi Yasukochi,5 Motoyoshi Kawataki,6 Hitoshi Horigome,7 Hitoshi Yoda,8 
Mio Taketazu,9 Makio Shozu,10 Masaki Nii,11 Akiko Hagiwara,12 Hitoshi Kato,13 
Wataru Shimizu,14 Isao Shiraishi,15 Heima Sakaguchi,15 Keiko Ueda,1 
Shinji Katsuragi,1 Tomoaki Ikeda,16 Haruko Yamamoto,17 Toshimitsu Hamasaki,18 
Japan Fetal Arrhythmia Group
To cite: Miyoshi T, Maeno Y, 
Sago H, et al.  Antenatal 
antiarrhythmic treatment for 
fetal tachyarrhythmias: a study 
protocol for a prospective 
multicentre trial. BMJ Open 
2017;7:e016597. doi:10.1136/
bmjopen-2017-016597
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
016597).
Received 25 February 2017
Revised 24 May 2017
Accepted 25 July 2017
For numbered affiliations see 
end of article.
correspondence to
Dr Yasuki Maeno;  
 yasukim@ med. kurume- u. ac. jp
Protocol
strengths and limitations of this study
 ► This is the first multicentre prospective study to 
confirm the efficacy and safety of the protocol-
defined transplacental treatment of fetal 
tachyarrhythmias.
 ► Fetal treatment protocol was carefully constructed 
depending on the ratio of atrioventricular and 
ventriculoatrial intervals by using fetal Doppler 
echocardiography.
 ► A possible limitation is related to the single-arm 
interventional study. The results of our retrospective 
survey and historical control data from the literature 
are referenced in designing this clinical study.
 ► Results will be limited to the efficacy of digoxin, 
sotalol and flecainide for fetal supraventricular 
tachycardia and atrial flutter.
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Figure 1 Summary of the study design.
accurately predict the natural prognosis of the disease. 
Available data suggest that the risk of fetal death will be 
elevated if tachyarrhythmia is left untreated in fetuses 
with fetal hydrops.
It has long been known that administration of anti-
arrhythmic drugs in a pregnant woman with fetal 
tachyarrhythmia has improvements in sinus rhythm of 
her fetus, and efforts have been made for transplacental 
treatment.7–10 Those interventions typically have reported 
improvements in sinus rhythm in ≥80% of fetuses without 
fetal hydrops. In addition, many studies have reported 
the therapeutic effectiveness in fetuses with fetal hydrops. 
Reported successes in transplacentally treating fetal 
tachyarrhythmia, combined with the relative ease of the 
procedure, have increased the popularity of this approach 
in Japan and many other countries. Accumulated evidence 
of transplacental pharmacotherapy for fetal tachyar-
rhythmia has prompted obstetricians and paediatricians to 
establish a standard protocol for this approach. Although 
a lot of institutions have reported standardised protocols, 
majority of reports are single-centre retrospective studies. 
These reports have limitation in design, including institu-
tion biases and differences in the inclusion or exclusion 
criteria. In addition, many of the retrospective studies are 
difficult to collect maternal, fetal and neonatal adverse 
events. To the best of our knowledge, there are only two 
prospective studies.10 11 However, these are single-centre 
and relatively small sample size which is less than 20 cases. 
Therefore, we are now performing the larger multicentre 
prospective study to confirm the efficacy and safety of the 
protocol-defined transplacental treatment of fetal tach-
yarrhythmias.
The choice of first and second-line antiarrhythmic 
therapy and criteria for decisions about management 
after initial treatment failure are controversial. In many 
centres, digoxin, administered maternally either orally or 
intravenously, is used as first-choice therapy because of its 
relatively safe profile, its long history of use during preg-
nancy and the familiarity with its use. Sotalol, flecainide 
and amiodarone have all been used as second-choice 
therapy.12–14 However, amiodarone has a more significant 
toxicity profile for the mother and fetus.14 Therefore, we 
selected digoxin as the first-choice drug, sotalol as the 
second-choice drug and flecainide as the third-choice 
drug in this study protocol. Digoxin has been explained 
by incomplete passage of the drug across the placenta, 
whereas sotalol and flecainide continue to cross the 
placenta readily even if there is fetal hydrops and should 
be preferred for patients in heart failure. Combination 
therapy with sotalol or flecainide is selected in hydropic 
fetuses.
The precise identification of the mechanism underlying 
a tachyarrhythmia is important since the pharmacological 
approach can be quite different. It is important to give 
the most efficient drug at the lowest possible dose and to 
avoid as much as possible blind trials of multiple drugs 
that increase the risk of maternal and fetal morbidity. 
To classify tachyarrhythmia, the efficacy of AV and 
ventriculoatrial (VA) intervals based on Doppler echocar-
diography is reported.11 15 16 Short VA SVT is the typical 
pattern in re-entry tachycardia. All drugs can be expected 
to be effective against the majority of re-entrant tachy-
cardia found in utero. In this study protocol, digoxin is 
used as first-choice therapy because of the vast experi-
ence gained with this agent in prenatal antiarrhythmic 
treatment. On the other hand, long VA SVT is rare tachy-
cardia, suggesting atrial ectopic tachycardia or permanent 
junctional reciprocating tachycardia. Since digoxin was 
reported to be ineffective in the long VA SVT,17 sotalol is 
used as first-choice therapy in this study protocol.
The primary goal of this study is to develop clinical 
guidelines for safe and effective fetal tachyarrhythmia 
treatment. This required us to evaluate the current status 
of treatments and results in Japan, and demonstrate the 
safety and effectiveness of fetal therapy in a rigorous clin-
ical trial. Therefore, we planned a multicentre prospective 
study to confirm the efficacy and safety of the protocol-de-
fined transplacental treatment of fetal tachyarrhythmias.
MEthods
Study design
This trial is a multicentre, single-arm interventional study. 
Figure 1 shows the study design in detail.
study period
The planned study period is from the ethics approval 
to March 2021. The patient registration period will last 
until December 2017. The neonatal evaluation period 
will continue until 1 month after the last delivery. Data 
collected by the end of the neonatal evaluation period 
will be subjected to statistical analysis. The children’s 
growth and development will be followed up for 3 years 
after birth. Growth and development assessments will be 
defined in more details according to a separate protocol.
sample size
Sample size in this study is 50 fetuses. The target disorders 
of this clinical study are very rare, with a rate of 1 out of 
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1000 pregnancies. At the National Cerebral and Cardio-
vascular Center, six cases were treated in the period from 
2004 to 2006. We expect that a total of 50 cases will be 
treated over a 5-year period at the participating study 
sites. A sample size of 50 produces a two-sided, Clop-
per-Pearson exact 95% CI with a width equal to 18.5 when 
the sample proportion is assumed 90%.
Endpoints
The primary endpoint of this study is disappearance of 
fetal tachyarrhythmia. The disappearance or dissipa-
tion of fetal tachyarrhythmia must fulfil either or both 
of the following conditions: normal sinus rhythm or 
mean heart rate <180 bpm. The secondary endpoints 
are fetal death definitely or probably related to tachyar-
rhythmia, proportion of preterm birth, rate of caesarean 
section attributable to fetal arrhythmia, improvement in 
heart rate and oedema after the fetal therapy, neonatal 
arrhythmia rate, neonatal central nervous system disor-
ders and survival at 1 month of age.
The safety endpoints are maternal, fetal and neonatal 
adverse events. Maternal adverse events are arrhythmia, 
ECG abnormalities, hepatic or renal dysfunction, 
dizziness, nausea, vomiting and worsening or onset 
of obstetric complications, such as preterm delivery, 
gestational hypertension, haemorrhage and gestational 
diabetes mellitus. ECG abnormalities are defined as 
PR prolongation, AV block, QT prolongation of more 
than 500 ms, and so on. Fetal adverse events are brady-
cardia, organ dysfunction and a new onset of arrhythmia. 
Neonatal adverse events are arrhythmia, ECG abnormal-
ities, hepatic or renal dysfunction, respiratory disorders, 
sustained cyanosis and jaundice.
Patient selection
Inclusion criteria are as follows: (1) sustained fetal tach-
yarrhythmia ≥180 bpm, with a diagnosis of SVT or AFL. 
Fetal tachyarrhythmia is defined as sustained when 
present ≥50% during a 40 min fetal heart rate monitoring 
or 30 min echocardiography session; (2) 22 to <37 weeks 
of gestation; (3) singleton pregnancy; (4) the parents’ 
written consent to study participation.
Exclusion criteria are as follows: (1) the mother has 
mental or psychiatric conditions that preclude safe study 
participation; (2) the mother is anticipated to be contra-
indicated to the antiarrhythmic medications; (3) the fetus 
is diagnosed to have serious and life-threatening malfor-
mations; (4) the fetus is diagnosed with multifocal atrial 
tachycardia or chaotic atrial tachycardia; (5) the mother 
or fetus is not eligible, in the investigator’s judgement, 
for this clinical study for reasons other than those above.
subjects and diagnostic methods
This clinical trial includes fetuses with SVT or AFL. These 
are diagnosed by using fetal echocardiography. SVT is 
defined as a tachyarrhythmia of supraventricular origin, 
characterised by 1:1 AV conduction. Depending on the 
ratio of AV and VA intervals, SVTs with a VA interval 
shorter than the AV (ie, VA/AV ratio <1) are designated 
as ‘short VA,’ and SVTs with a VA interval longer than 
the AV (ie, VA/AV ratio >1) are designated as ‘long VA.’ 
The VA interval relates to the time between the onset 
of a ventricular (V) waveform to the onset of an atrial 
(A) waveform, while the AV interval relates to the time 
between the onset of an A waveform to the onset of a V 
waveform. The classification of short and long VA types 
of fetal tachyarrhythmia will primarily be made based on 
Doppler echocardiography, with supplementary assis-
tance of M-mode echocardiography. VA intervals will be 
determined according to one of the following methods 
that evaluate: (1) waveforms of the ascending aorta and 
superior vena cava; (2) waveforms of the left ventricular 
inflow and outflow; (3) pulmonary artery and vein wave-
forms. If the SVT cannot be classified as either long or 
short VA type for certain reasons, it will be categorised as 
the short VA type for the sake of initiating study treatment. 
Fetuses diagnosed with multifocal atrial tachycardia or 
chaotic atrial tachycardia will be excluded from this study. 
AFL is defined as a tachyarrhythmia of supraventricular 
origin, characterised by 2:1 or greater AV conduction rate 
due to AV blocking. To ensure the diagnostic accuracy, 
the investigator will record the fetal ultrasound scans 
(photo or video) at the time of diagnosis, and the scans 
will be reviewed by the Protocol Evaluation Committee.
registration
Patients who satisfy all inclusion criteria and do not meet 
any of the exclusion criteria will be eligible for inclusion 
in the study. Individual study sites will be responsible for 
guiding potential participants through the informed 
consent process, including those patients who have been 
referred to them for treatment purposes. The investi-
gator will enter an eligible patient’s information into the 
Eligibility Confirmation Form and send it by fax to the 
Secretariat in the National Cerebral and Cardiovascular 
Center. The Secretariat will check the contents of the 
form before registering the patient. Enrolled participants 
will receive fetal therapy within 7 days of registration.
The Protocol Evaluation Committee is an organisa-
tion independent of the execution of this study. This 
committee will review the accuracy of the fetal diagnosis 
retrospectively to ensure the overall quality of this clinical 
study. As a basic rule, the opinion of this committee will 
not impact the fetal therapy or other treatment-related 
aspects of this clinical study. The investigator will mail 
the ultrasound video of each registered mother recorded 
at diagnosis to the Protocol Evaluation Committee. At 
the completion of this study, the Protocol Evaluation 
Committee will review the legitimacy of the diagnosis and 
handling of the subjects.
Independent safety Evaluation committee
The Independent Safety Evaluation Committee (ISEC) 
is responsible for the overall safety of this clinical study. 
To ensure the safety of the protocol-defined treatment, 
the ISEC will review the doses and adverse events of 
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Figure 2 Overview of the fetal treatment protocol. AFL, atrial 
flutter; SVT, supraventricular tachycardia; VA, ventriculoatrial.
digoxin, flecainide and sotalol. Specifically, the safety of 
digoxin will be reviewed when the data on the first three 
cases are obtained. The safety of flecainide and sotalol 
will be reviewed when the data on the first case and the 
first three cases are available. Every serious adverse event 
will provide the Secretariat within 24 hours of its onset 
according to the predetermined procedure. The Secre-
tariat then will forward the obtained information without 
delay to the ISEC for review. The ISEC will notify the 
investigator of the review results. The serious adverse 
events will also be reviewed by the ethics committees in 
the participating institutions including the National Cere-
bral and Cardiovascular Center according to the Japanese 
Ethical Guidelines for Clinical Studies and the regulatory 
notifications regarding the Japanese Advanced Investiga-
tional Medical Care Evaluation Program.
treatment methods
This study protocol defines all the procedures and sched-
ules that the investigator must abide by to complete this 
clinical study, including patient selection and registra-
tion, transplacental treatment of fetal tachyarrhythmia 
and follow-up. Registered patients will receive the 
protocol-defined fetal treatment. As a general rule, the 
fetal therapy will be administered under 24 hours ECG 
monitoring in an inpatient setting. The investigator 
will provide standard pregnancy care, and the pregnant 
woman will undergo vaginal or caesarean delivery at 37 
or more weeks of gestation. If the investigator judges 
that the pregnancy cannot be maintained to term due 
to obstetric indications, the investigator will give birth to 
the fetus according to the Criteria for Delivery (termi-
nation of the fetal therapy). If no positive treatment 
effect is observed in a fetus at 37 gestational weeks, the 
investigator will consider delivering the fetus without 
proceeding to further stages of treatment (ie, second 
or third option or dose increase). If the investigator 
continues the fetal therapy beyond 37 gestational weeks 
even when fetal therapy is not effective, the fetus will be 
classified as non-compliant. The investigator must present 
a written report that explains the reason for the contin-
uation. Fetuses who completed the fetal therapy will be 
followed up according to the study schedule. Fetuses in 
whom the fetal therapy was prematurely discontinued as 
per the stopping criteria will receive scheduled examina-
tions and other assessments to the extent possible. The 
stopping criteria define three major conditions: serious 
adverse drug reactions, death and withdrawal of consent 
to study participation. If the fetal therapy is prematurely 
discontinued due to a serious adverse drug reaction to 
the antiarrhythmic drug, scheduled subsequent examina-
tions and other assessments should be continued to the 
extent possible. If either the mother or fetus dies during 
the study period (fetal death, maternal death or postnatal 
death), the study treatment will be discontinued at this 
time point. If the mother withdraws her consent to study 
participation, she and her fetus will be removed from 
the study. If a registered mother or her fetus is found to 
have been non-conformant to the eligibility criteria, the 
mother or fetus will be categorised as non-compliant.
Fetal treatment protocol
The investigator will provide the fetal therapy as described 
below. If the investigator finds a positive effect (ie, disap-
pearance of, or improvement in, fetal tachyarrhythmia, 
see the efficacy endpoints for reference), the investigator 
will continue the treatment until delivery. If the mother or 
fetus develops adverse drug reactions to digoxin, sotalol 
or flecainide, the investigator will either discontinue the 
drug or reduce its dose at his or her discretion. Overview 
of the fetal treatment protocol is shown in figure 2.
Fetuses with short VA sVt or AFL
If the fetus has non-hydrops, the fetal therapy will start 
with the first-choice therapy. If the fetus is unresponsive 
to the first-choice therapy, the treatment will proceed to 
the next step. In cases with fetal hydrops, the fetal therapy 
will start with the second-choice therapy.
First-choice therapy: digoxin (injections or tablets)
Rapid saturation is initially performed by 0.5 mg intrave-
nous injection. A 0.25 mg intravenous injection will be 
administered 8 and 16 hours after the initial dose. If intra-
venous injections are not feasible, oral administration is 
performed by 1.5 mg/day in three divided doses. Main-
tenance oral administration is subsequently performed 
by 0.75 mg/day in three divided doses. The target blood 
concentration range is 1.5–2.0 ng/mL. The maintenance 
doses may be adjusted based on blood concentration 
measurements. The therapy will be judged ineffective 
if the fetal arrhythmia does not disappear or improve 3 
or more days after the establishment of the target blood 
level. The investigator will move to the second-choice 
therapy.
Second-choice therapy: combination of digoxin (injections or 
tablets) and sotalol (tablets)
Digoxin is administered or maintained same as the 
first-choice therapy. Sotalol is administered 160 mg/
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day in two divided doses as combination therapy. If no 
improvement is seen with 160 mg/day within 3 days of 
treatment, proceed to 240 mg/day in two divided doses. If 
no improvement is seen with 240 mg/day within 3 days of 
treatment, proceed to 320 mg/day in two divided doses. 
Sotalol must be discontinued if prolongation of the QT 
interval is noted (corrected QT interval >0.5 s). The 
therapy will be judged ineffective if the fetal arrhythmia 
does not disappear or improve 3 or more days after the 
start of the highest sotalol dose. The investigator will 
move to the third-choice therapy.
Third-choice therapy: combination of digoxin (injections or tablets) 
and flecainide (tablets)
Digoxin is maintained same as the first-choice therapy. 
When starting flecainide, the investigator will continue 
digoxin but discontinue sotalol. Flecainide is adminis-
tered 200 mg/day in two divided doses as combination 
therapy. If no improvement is seen with 200 mg/day 
within 3 days of treatment, proceed to 300 mg/day in 
two divided doses. Flecainide must be discontinued if 
prolongation of the QT interval is noted (corrected QT 
interval >0.5 s). The therapy will be judged ineffective if 
the fetal tachyarrhythmia does not disappear or improve 
3 or more days after the start of the highest flecainide 
dose.
Fetuses with long VA sVt
The first-choice therapy is sotalol, regardless of the pres-
ence or absence of fetal hydrops. When switching to 
flecainide, the investigator will discontinue sotalol. The 
dosage and administration requirements are the same as 
those for fetuses with short VA SVT.
1. first-choice therapy: sotalol (tablets)
2. second-choice therapy: flecainide (tablets)
Fetuses unresponsive to therapy
The fetus is defined as unresponsive to the fetal therapy if 
the fetal tachyarrhythmia does not disappear or improve 
after treatment with all available options, or the risk of 
fetal death is strongly suspected due to aggravation of 
fetal hydrops. The risk of fetal death is strongly suspected 
if: (1) fetal hydrops continues for 2 or more weeks, or 
the fetal heart rate is ≥180 bpm in the absence of signs 
of improvement in subcutaneous oedema; (2) fetal 
hydrops continues for 1 or more weeks, or the fetal heart 
rate is ≥220 bpm in the absence of signs of improvement 
in subcutaneous oedema; (3) the fetal heart rate moni-
toring depicts worsening conditions. If the fetus is judged 
unresponsive to the fetal therapy, the investigator must 
discontinue the protocol-defined treatment. At his or 
her discretion, the investigator will decide to deliver the 
fetus for neonatal treatment or to start other fetal phar-
macotherapies. Preferably, the investigator should deliver 
the fetus by caesarean section, if worsening fetal hydrops 
strongly suggests progression to fetal death. The investi-
gator should continue collecting data on unresponsive 
patients.
stopping criteria
The investigator must discontinue the protocol-defined 
treatment when certain events prevent continuation of 
the protocol treatment, which include the following: (1) a 
serious adverse drug reaction to the antiarrhythmic drug 
has developed during the fetal therapy; (2) the investi-
gator’s decision to prioritise other therapies than the 
fetal therapy. When the fetus’s parents have withdrawn 
their consent to study participation, the investigator must 
discontinue the protocol-defined treatment.
criteria for delivery
In responded cases, the investigator should deliver the 
fetus if: (1) onset of labour; (2) maternal indications 
suggest that continued pregnancy will cause adverse 
health effects to the mother; (3) fetal indications suggest 
an urgent need for delivery. The standard obstetric indi-
cations for caesarean section are applicable in this study. 
The investigator will choose the safest method for the 
mother and child. Caesarean section is recommended if 
the investigator cannot monitor the fetal heart rate.
In non-responded cases, the investigator should deliver 
the fetuses following the previously described criteria in 
‘fetuses unresponsive to therapy’ and ‘stopping criteria’.
Follow-up
The investigator will evaluate the growth and develop-
ment of the infant subjects. For the follow-up evaluation 
of the growth and development of the infant subjects, the 
investigator may ask for the help of developmental paedi-
atricians at own or other medical centres that participate 
in the Japanese Neonatologist Association. At 18 and 36 
months of age, growth and development are assessed. 
Growth parameters include height, weight, head and 
chest circumferences. The standard growth charts will 
be used for reference. The proportion of infants who 
walk alone and have a vocabulary of three or more words 
will be determined. The Kyoto Scale of Psychological 
Development may preferably be used for developmental 
assessment. The Kyoto scale, standardised neurodevel-
opment assessment method in Japan, is reported to be 
well correlated to Bayley III scale for the neurodevelop-
ment follow-up in the cases with very low birth infant. The 
motor, cognitive and language scores, which are repre-
senting specific areas in child development, correlated 
well between the two tests.18
statistical analysis
Analyses are done in all fetuses’ patients recruited into 
the study as a primary analysis population, and then per 
protocol set (ie, removing patients who do not meet the 
inclusion and exclusion criteria) as a secondary analysis 
population for sensitivity analysis. All outcome measures 
are presented as summaries of descriptive statistics 
(mean (SD) or median (minimum and maximum) for 
continuous measures, and the numbers and propor-
tions for ordinal and dichotomous measures). For the 
primary endpoint, that is, the disappearance of fetal 
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tachyarrhythmia, an exact CI for the proportion is calcu-
lated using Clopper-Pearson method. All analyses are 
performed according to a prespecified statistical analysis 
plan using SAS V.9.3 or later (SAS Institute). The Data 
Coordinating Center at the National Cerebral and Cardio-
vascular Research Center supports the data management, 
and statistical analysis and reporting of the study.
Participating institutions
Case registration requires the approval of the Ethics 
Committee and Advanced Medical Technology Center. 
The following institutions will participate in this clin-
ical trial: National Cerebral and Cardiovascular Center, 
Kurume University School of Medicine, Osaka Medical 
Center and Research Institute for Maternal and Child 
Health, National Center for Child Health and Develop-
ment, Kanagawa Children’s Medical Center, Tsukuba 
University, Toho University Omori Medical Center, 
Hokkaido University, Hyogo Prefectural Children’s 
Hospital, Nagano Prefectural Children’s Hospital, 
Shizuoka Prefectural Children’s Hospital, Kobe City 
Medical Center Hospital, Mie University, Okayama 
Medical Center and Osaka University.
dIscussIon
To the best of our knowledge, this is the first multicentre 
clinical trial designed to evaluate the efficacy and safety 
of the protocol-defined transplacental treatment of fetal 
tachyarrhythmias.
Prior to designing this clinical trial, we conducted a 
nationwide survey in Japan from 2004 to 2006 for the 
purpose of grasping the status of fetal tachyarrhythmia 
therapy. This study was the first of its kind conducted in 
Japan. A total of 82 cases were analysed. Forty-one cases 
(50%) were treated in utero. This survey showed that fetal 
tachyarrhythmia therapy is fairly common, reporting 
improvements in tachycardia in 37 (90.2%) of 41 cases. 
Improvements were also reported in 9 (81.8%) of 11 
cases of fetal hydrops. These results were comparable 
with previous reports.3–8 One death each was documented 
in treated and untreated cases. The small number of 
deaths is probably attributable to proactive interventions 
informed by previous studies, in which high-risk fetuses 
had been treated early before the onset of fetal hydrops 
or underwent preterm delivery. These data indicated 
that untreated fetuses with tachyarrhythmia would have a 
much lower mortality rate than that reported in the liter-
ature under the natural course of the disease, suggesting 
that improvement in mortality would not be an adequate 
endpoint of this clinical study. Our survey also showed 
that the treated cases were associated with low propor-
tions of preterm delivery, caesarean section and neonatal 
tachyarrhythmia. These data suggested that fetal therapy 
improves perinatal maternal and fetal safety.
Based on the above, we have designed this clinical study 
to establish evidence for fetal tachyarrhythmia therapy. 
With the participation of many major medical centres 
providing fetal therapy, this study will evaluate the safety 
and effectiveness of the protocol developed by the Fetal 
Arrhythmia Group of the Research Team for Evidence-
Based Fetal Therapy (principal investigator: Dr Sago), 
which was funded under the Health Labour Science 
Research Grant Program in Japan. The retrospective 
survey mentioned earlier presents current clinical results 
of fetal therapy in Japan, which are expected to serve as 
the control for this prospective study. These data and 
historical control data from the literature were referenced 
in designing this clinical study. Therefore, we planned a 
multicentre single-arm interventional study to confirm 
the efficacy and safety of the protocol-defined transpla-
cental treatment of fetal tachyarrhythmias.
Our retrospective survey showed that improvements in 
tachyarrhythmia led to improvements in fetal hydrops, 
pregnancy maintenance and preterm birth prevention 
(preterm delivery rate: 12.2% in treated group vs 41.5% 
in untreated group), a lower frequency of caesarean 
section (29.7% in treated group vs 70.7% in untreated 
group) and a lower frequency of fetal arrhythmia (48.8% 
in treated group vs 78.0% in untreated group). These 
have been included as secondary efficacy endpoints. 
Moreover, this study has been designed to investigate 
long-term infant growth and development (up to 36 
months of age), which are seldom reported in fetal 
therapy follow-up.19 20
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